Td Asset Management Inc Cure Vac N.V. Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$6.5 - $10.77 $544,355 - $901,955	83,747 Added 66.81%	209,094 $1.43 Million
Q2 2023 Aug 09, 2023	SELL	$6.69 - $12.25 $182,295 - $333,800	-27,249 Reduced 17.86%	125,347 $1.31 Million
Q1 2023 May 10, 2023	BUY	$6.38 - $12.5 $715,172 - $1.4 Million	112,096 Added 276.78%	152,596 $1.06 Million
Q4 2022 Feb 06, 2023	BUY	$5.75 - $8.5 $232,875 - $344,250	40,500 New	40,500 $244,000
Q2 2022 Aug 04, 2022	SELL	$13.18 - $19.41 $459,982 - $677,409	-34,900 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$49.26 - $74.5 $1.72 Million - $2.6 Million	34,900 New	34,900 $1.91 Million
Q2 2021 Aug 11, 2021	SELL	$56.91 - $127.53 $2 Million - $4.48 Million	-35,125 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$79.79 - $126.29 $478,341 - $757,108	5,995 Added 20.58%	35,125 $3.21 Million
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $1.36 Million - $3.97 Million	29,130 New	29,130 $2.36 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.